Unjha Formulations Ltd: Valuation Shift Enhances Price Attractiveness Amid Sector Challenges

Valuation Metrics and Market Context

As of 20 Aug 2026, Unjha Formulations trades at ₹26.13, down 4.95% on the day from a previous close of ₹27.49. The stock’s 52-week range spans ₹17.52 to ₹29.50, indicating a relatively narrow trading band with recent price consolidation near the upper end. Despite the recent dip, the company’s valuation metrics have improved, signalling a more compelling entry point for investors.

The company’s price-to-earnings (P/E) ratio stands at 24.39, a figure that has shifted the valuation grade from fair to attractive. This P/E is notably lower than several peers in the Pharmaceuticals & Biotechnology sector, such as Fredun Pharma (P/E 53.63) and Shukra Pharma (P/E 55.35), which are classified as very expensive. Even compared to Venus Remedies, rated fair with a P/E of 20.36, Unjha’s valuation appears reasonable given its growth prospects and profitability metrics.

Similarly, the price-to-book value (P/BV) ratio of 3.05 supports the attractive valuation narrative. While not the lowest in the sector, it is considerably more modest than some peers with elevated multiples, reflecting a more balanced price relative to the company’s net asset base.

Profitability and Efficiency Indicators

Unjha Formulations boasts a robust return on capital employed (ROCE) of 40.91%, underscoring efficient utilisation of capital to generate earnings. Its return on equity (ROE) of 12.50% further confirms the company’s ability to deliver shareholder returns, albeit at a moderate level compared to sector heavyweights. These profitability metrics provide a solid foundation for the current valuation, suggesting that the market is beginning to recognise the company’s operational strengths.

The enterprise value to EBITDA (EV/EBITDA) ratio of 10.07 also indicates a reasonable valuation relative to earnings before interest, taxes, depreciation, and amortisation. This multiple is significantly lower than peers such as Ind-Swift Labs (EV/EBITDA 39.88) and Hester Biosciences (EV/EBITDA 25.84), which are classified as very expensive, highlighting Unjha’s relative value proposition.

Comparative Peer Analysis

When benchmarked against its sector peers, Unjha Formulations emerges as a relatively attractive investment candidate. Its P/E ratio of 24.39 is substantially lower than the likes of Fredun Pharma and Shukra Pharma, which trade at more than double this multiple. The PEG ratio, a measure of valuation relative to earnings growth, is exceptionally low at 0.06, suggesting that the stock is undervalued relative to its growth potential. This contrasts sharply with peers such as Fredun Pharma (PEG 0.85) and Jagsonpal Pharma (PEG 2.38), which appear overvalued on this metric.

Moreover, Unjha’s EV to capital employed ratio of 4.58 and EV to sales of 0.66 further reinforce its valuation appeal, indicating that the market is pricing the company conservatively relative to its asset base and revenue generation.

Stock Performance Versus Sensex

Unjha Formulations has outperformed the benchmark Sensex over multiple time horizons, highlighting its resilience and growth trajectory. Year-to-date, the stock has delivered a positive return of 4.52%, while the Sensex has declined by 9.75%. Over one year, Unjha’s gain of 5.79% contrasts with the Sensex’s negative 5.80%. The outperformance is even more pronounced over longer periods, with a three-year return of 101.31% versus the Sensex’s 18.42%, and a five-year return of 163.94% compared to the Sensex’s 38.25%. Over a decade, Unjha has delivered a remarkable 205.97% return, outpacing the Sensex’s 173.92%.

These figures underscore the company’s ability to generate shareholder value consistently, even as it navigates sectoral and macroeconomic challenges.

Mojo Score and Rating Update

MarketsMOJO’s proprietary scoring system assigns Unjha Formulations a Mojo Score of 44.0, with a current Mojo Grade of Sell. This represents an upgrade from a previous Strong Sell rating as of 10 Aug 2026, reflecting improved valuation and operational metrics. The upgrade signals a cautious optimism among analysts, recognising the company’s enhanced price attractiveness while acknowledging ongoing risks inherent to micro-cap stocks in the Pharmaceuticals & Biotechnology sector.

Risks and Considerations

Despite the improved valuation, investors should remain mindful of the stock’s volatility and sector-specific risks. The day’s price decline of 4.95% highlights sensitivity to market sentiment and potential liquidity constraints typical of micro-cap stocks. Additionally, the absence of a dividend yield may deter income-focused investors, while the company’s PEG ratio, though low, warrants scrutiny to ensure sustainable earnings growth.

Outlook and Investment Implications

Unjha Formulations’ shift to an attractive valuation grade presents a compelling case for investors seeking exposure to the Pharmaceuticals & Biotechnology sector at a reasonable price point. The company’s strong ROCE and ROE, combined with favourable EV multiples, suggest operational efficiency and prudent capital management. Its consistent outperformance relative to the Sensex over medium and long-term periods further bolsters its investment appeal.

However, the current Mojo Grade of Sell advises a measured approach, recommending that investors weigh the company’s fundamentals against broader market conditions and peer valuations before committing capital.

Conclusion

Unjha Formulations Ltd’s recent valuation upgrade from fair to attractive is underpinned by improved price multiples, strong profitability metrics, and consistent market outperformance. While the stock remains a micro-cap with inherent risks, its relative valuation compared to sector peers and historical benchmarks offers a renewed opportunity for investors seeking growth in the Pharmaceuticals & Biotechnology space. The cautious upgrade in Mojo Grade to Sell from Strong Sell reflects a balanced view, encouraging investors to consider the stock within a diversified portfolio and monitor ongoing developments closely.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →